{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:45:44Z","timestamp":1777506344609,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jjcc.2020.10.016","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T19:17:16Z","timestamp":1606418236000},"page":"620-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["New treatment for myocardial diseases"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3233-4913","authenticated-orcid":false,"given":"Kenji","family":"Onoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9372","key":"10.1016\/j.jjcc.2020.10.016_bib0005","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(03)13501-5","article-title":"Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study","volume":"361","author":"Jong","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jjcc.2020.10.016_bib0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jjcc.2020.10.016_bib0015","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jjcc.2020.10.016_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"Beta Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jjcc.2020.10.016_bib0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cardiores.2005.04.027","article-title":"Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights","volume":"67","author":"Kontula","year":"2005","journal-title":"Cardiovasc Res"},{"issue":"12","key":"10.1016\/j.jjcc.2020.10.016_bib0030","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.tibs.2016.09.006","article-title":"How myosin generates force on actin filaments","volume":"41","author":"Houdusse","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jjcc.2020.10.016_bib0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev.biophys.050708.133751","article-title":"Structural and functional insights into the Myosin motor mechanism","volume":"39","author":"Sweeney","year":"2010","journal-title":"Annu Rev Biophys"},{"issue":"6956","key":"10.1016\/j.jjcc.2020.10.016_bib0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature02005","article-title":"Electron cryo-microscopy shows how strong binding of myosin to actin releases nucleotide","volume":"425","author":"Holmes","year":"2003","journal-title":"Nature"},{"issue":"6023","key":"10.1016\/j.jjcc.2020.10.016_bib0045","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: a potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik","year":"2011","journal-title":"Science"},{"issue":"10062","key":"10.1016\/j.jjcc.2020.10.016_bib0050","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic Oral Study of Myosin Activation to increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jjcc.2020.10.016_bib0055","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/eurjhf\/hfs191","article-title":"Gender-specific differences in major cardiac events and mortality in lamin A\/C mutation carriers","volume":"15","author":"van Rijsingen","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jjcc.2020.10.016_bib0060","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41598-018-20114-9","article-title":"Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling","volume":"8","author":"Tobita","year":"2018","journal-title":"Sci Rep"},{"issue":"19","key":"10.1016\/j.jjcc.2020.10.016_bib0065","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1093\/hmg\/dds265","article-title":"Abnormal p38alpha mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A\/C gene mutation","volume":"21","author":"Muchir","year":"2012","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1016\/j.jjcc.2020.10.016_bib0070","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.jjcc.2020.10.016_bib0075","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jjcc.2020.10.016_bib0080","first-page":"e783","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"issue":"39","key":"10.1016\/j.jjcc.2020.10.016_bib0085","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Authors\/Task Force m","year":"2014","journal-title":"Eur Heart J"},{"issue":"6273","key":"10.1016\/j.jjcc.2020.10.016_bib0090","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"issue":"35","key":"10.1016\/j.jjcc.2020.10.016_bib0095","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.jjcc.2020.10.016_bib0100","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10253","key":"10.1016\/j.jjcc.2020.10.016_bib0105","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jjcc.2020.10.016_bib0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.jjcc.2020.10.016_bib0115","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.jjcc.2020.10.016_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3892\/ijmm.2012.1187","article-title":"New strategies for the treatment of lysosomal storage diseases (review)","volume":"31","author":"Parenti","year":"2013","journal-title":"Int J Mol Med"},{"issue":"5","key":"10.1016\/j.jjcc.2020.10.016_bib0125","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.jjcc.2020.10.016_bib0130","doi-asserted-by":"crossref","DOI":"10.1038\/s41431-020-0677-x","article-title":"Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data","author":"Riccio","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jjcc.2020.10.016_bib0135","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12228","article-title":"Developments in the treatment of Fabry disease","author":"van der Veen","year":"2020","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.jjcc.2020.10.016_bib0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/hrt.2009.190405","article-title":"Amyloid diseases of the heart: assessment, diagnosis, and referral","volume":"97","author":"Dubrey","year":"2011","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.jjcc.2020.10.016_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho","year":"2016","journal-title":"Neurol Ther"},{"issue":"11","key":"10.1016\/j.jjcc.2020.10.016_bib0150","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jjcc.2020.10.016_bib0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jjcc.2020.10.016_bib0160","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2020.10.016_bib0165","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","author":"Habtemariam","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.jjcc.2020.10.016_bib0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11886-017-0870-x","article-title":"Myocarditis: a clinical overview","volume":"19","author":"Caforio","year":"2017","journal-title":"Curr Cardiol Rep"},{"issue":"9","key":"10.1016\/j.jjcc.2020.10.016_bib0175","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the inflammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jjcc.2020.10.016_bib0180","article-title":"The treatment of adult-onset Still\u2019s disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature","author":"Giacomelli","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jjcc.2020.10.016_bib0185","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3389\/fphar.2019.00918","article-title":"Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease","volume":"10","author":"Sota","year":"2019","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.jjcc.2020.10.016_bib0190","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1097\/TP.0000000000002765","article-title":"MHC-mismatched allotransplantation of induced pluripotent stem cell-derived cardiomyocyte sheets to improve cardiac function in a primate ischemic cardiomyopathy model","volume":"103","author":"Kashiyama","year":"2019","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.jjcc.2020.10.016_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2017.11.010","article-title":"Direct in vivo reprogramming with sendai virus vectors improves cardiac function after myocardial infarction","volume":"22","author":"Miyamoto","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"2","key":"10.1016\/j.jjcc.2020.10.016_bib0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jjcc.2018.10.002","article-title":"Progress and challenge of cardiac regeneration to treat heart failure","volume":"73","author":"Isomi","year":"2019","journal-title":"J Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508720303543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508720303543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:04:21Z","timestamp":1760274261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508720303543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0914508720303543"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2020.10.016","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatment for myocardial diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2020.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese College of Cardiology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}